The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
AACR 2023 | GUK1 as a driver of resistance to targeted therapies in lung cancer
Jaime Schneider, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the role of GUK1, a guanylate kinase, in the resistance to targeted therapies in lung cancer. Resistance to targeted therapies is currently an unmet need, and GUK1 was identified as a novel metabolic liability in a radiomic and metabolic analysis. Post-translational modification of the enzyme enables tumor proliferation, and is mainly observed in ALK-driven lung cancer. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
